Long-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytes

被引:24
|
作者
Tolosa, Laia [1 ]
Jimenez, Nuria [1 ]
Pelecha, Maria [1 ]
Castell, Jose V. [1 ,2 ]
Jose Gomez-Lechon, Ma [1 ]
Teresa Donato, M. [1 ,2 ]
机构
[1] Torre A Inst Invest Sanitaria La Fe, Unidad Hepatol Expt, Av Fernando Abril Martorell 106, Valencia 46026, Spain
[2] Univ Valencia, Fac Med, Dept Bioquim & Biol Mol, Valencia 46010, Spain
关键词
Hepatotoxicity; Chronic toxicity; Mechanisms; Cell model; Preclinical evaluation; VALPROIC ACID METABOLISM; IN-VITRO MODEL; HEPARG CELLS; CHRONIC TOXICITY; HEPATOTOXICITY; CHLORPROMAZINE; BIOKINETICS; TECHNOLOGY; FLUTAMIDE; RAT;
D O I
10.1007/s00204-018-2349-y
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Drug-induced liver injury (DILI) constitutes one of the most frequent reasons of restricted-use warnings as well as withdrawals of drugs in postmarketing and poses an important concern for the pharmaceutical industry. The current hepatic in vivo and in vitro models for DILI detection have shown clear limitations, mainly for studies of long-term hepatotoxicity. For this reason, we here evaluated the potential of using Upcytes human hepatocytes (UHH) for repeated-dose long-term exposure to drugs. The UHH were incubated with 15 toxic and non-toxic compounds for up to 21 days using a repeated-dose approach, and, in addition to conventional examination of effects on viability, the mechanisms implicated in cell toxicity were also assessed by means of high-content screening. The UHH maintained the expression and activity levels of drug-metabolizing enzymes for up to 21 days of culture and became more sensitive to the toxic compounds after extended exposures, showing inter-donor differences which would reflect variability among the population. The assay also allowed to detect the main mechanisms implicated in the toxicity of each drug as well as identifying special susceptibilities depending on the donor. UHH can be used for a long-term repeated detection of DILI at clinically relevant concentrations and also offers key mechanistic features of drug-induced hepatotoxicity. This system is therefore a promising tool in preclinical testing of human relevance that could help to reduce and/or replace animal testing for drug adverse effects.
引用
收藏
页码:519 / 532
页数:14
相关论文
共 50 条
  • [21] TAK-994 mechanistic investigation into drug-induced liver injury
    Shinozawa, Tadahiro
    Miyamoto, Kazumasa
    Baker, Kevin S.
    Faber, Samantha C.
    Flores, Ramon
    Uetrecht, Jack
    von Hehn, Christian
    Yukawa, Tomoya
    Tohyama, Kimio
    Kadali, Harisha
    von Grotthuss, Marcin
    Sudo, Yusuke
    Smith, Erin N.
    Diogo, Dorothee
    Zhu, Andy Z. X.
    Dragan, Yvonne
    Cebers, Gvido
    Wagoner, Matthew P.
    TOXICOLOGICAL SCIENCES, 2025,
  • [22] Features of idiosyncratic drug-induced liver injury (DILI) in Latin America: Long-term experience of the Latindili network
    Sanabria Cabrera, J.
    Bessone, F.
    Hernandez, N.
    Arrese, M.
    Parana, R.
    Stephens, C.
    Medina Caliz, I.
    Alvarez Alvarez, I.
    Andrade Bellido, R. J.
    Lucena Gonzalez, M. I.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 135 : 18 - 19
  • [23] Outcome of acute idiosyncratic drug-induced liver injury:: Long-term follow-up in a hepatotoxicity registry
    Andrade, Raul J.
    Lucena, M. Isabel
    Kaplowitz, Neil
    Garcia-Munoz, Beatriz
    Borraz, Yolanda
    Pachkoria, Ketevan
    Garcia-Cortes, Miren
    Fernandez, M. Carmen
    Pelaez, Gloria
    Rodrigo, Luis
    Duran, Jose A.
    Costa, Joan
    Planas, Ramon
    Barriocanal, Anabel
    Guarner, Carlos
    Romero-Gomez, Manuel
    Munoz-Yague, Teresa
    Salmeron, Javier
    Hidalgo, Ramon
    HEPATOLOGY, 2006, 44 (06) : 1581 - 1588
  • [24] Oxidative-stress and long-term hepatotoxicity: comparative study in Upcyte human hepatocytes and hepaRG cells
    M. Teresa Donato
    Nuria Jiménez
    María Pelechá
    Laia Tolosa
    Archives of Toxicology, 2022, 96 : 1021 - 1037
  • [25] A drug for drug-induced liver injury?
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (03) : 177 - 177
  • [26] Drug-Induced Liver Injury
    Leise, Michael D.
    Poterucha, John J.
    Talwalkar, Jayant A.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (01) : 95 - 106
  • [27] Drug-Induced Liver Injury
    McAtee, Cathy
    CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2022, 34 (03) : 267 - 275
  • [28] Drug-Induced Liver Injury
    Almario, Eileen E. N.
    Borlak, Juergen
    Suzuki, Ayako
    Chen, Minjun
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [29] Drug-induced liver injury
    Denk, H
    PATHOLOGY OF THE KIDNEYS AND URINARY PASSAGES - MOLECULAR VASCULAR PATHOLOGY AND ANGIOGENESIS, 2002, 86 : 120 - 125
  • [30] Drug-induced liver injury
    Aithal, G.
    DRUG SAFETY, 2017, 40 (10) : 1040 - 1040